

## TENTATIVE PROGRAM

# 11<sup>TH</sup> NEUROLOGICAL DISORDERS SUMMIT

**JULY 06-08, 2026 | BOSTON, MA**

**FOUR POINTS BY SHERATON WAKEFIELD  
BOSTON HOTEL & CONFERENCE CENTER  
ONE AUDUBON RD, WAKEFIELD, MA**

**Sponsors and Partners**





## **Multi-Health Systems Inc. (MHS)**

***“By leveraging world-class science to address today’s most pressing challenges, we are creating better outcomes across every area we serve. This achievement reflects our unwavering commitment to innovation and excellence.”***

— John Clarke, Chief Executive Officer, MHS

### **Solutions Designed For**

#### **Clinical**

Browse MHS’ extensive collection of innovative, scientifically validated assessments and monitoring tools. These invaluable resources for psychologists, psychiatrists, and counselors help diagnose and treat mental health conditions, enabling personalized care that transforms lives.

#### **Education**

Explore MHS’ assessment solutions for school psychologists, special education personnel, and gifted and talented coordinators. These advanced assessments enable early intervention, personalized learning plans, and identification of gifted students, fostering an inclusive environment, enhancing student outcomes.

#### **Public Safety**

Learn more about how MHS’ public safety solutions are rooted in a person-centric approach, prioritizing the rehabilitation and community reintegration of justice-involved individuals. These tools streamline data management and decision-making processes, fostering safer communities.

#### **Talent**

Discover how MHS supports the employee lifecycle by equipping HR, learning and development, talent acquisition and change management professionals and advisors with our assessments and solutions. These tools enhance talent selection and leadership development, driving performance and fostering growth.

MHS is a leading developer of innovative assessments and solutions designed to measure and develop human potential.

For more than four decades, we have been at the forefront of creating groundbreaking tools to understand and address neurological conditions and disorders—including ADHD—in both children and adults. We are breaking barriers and transforming how gifted and talented youth are identified, championing fair and inclusive processes that recognize and nurture potential in all its forms.

We are equally committed to improving outcomes within the justice system by providing meaningful support and resources for both those impacted by the system and the professionals who work within it. At our core, we believe in empowering individuals at every level to achieve their full potential. This belief drives our continued innovation in talent development, with a strong focus on emotional intelligence, leadership development, and beyond.

Fairness, equity, and the relentless reduction of bias guide everything we do—from designing cutting-edge products to delivering impactful solutions and leading our teams. Our commitment extends beyond our work: we believe in giving back to the communities that shape us and embracing our responsibility to make a positive difference in the world.

Join us on our journey to create a future where everyone has the opportunity to succeed and thrive.

<https://mhs.com/>

# NDS-2026 ANNUAL CONFERENCE



## Kenneth Blum

Western University College of Medicine, USA  
Conference Co-chair

We welcome you to the 11<sup>th</sup> Neurological Disorders Summit (NDS-2026) on July 06-08, 2026, in Boston, USA.

The **NDS-2026** summit offers a unique opportunity for neuroscientists and physicians to share their research and experiences with leading experts in their fields. The program features keynote speeches from internationally renowned scientists who have shaped modern neuroscience concepts. Additionally, there will be sessions for oral and poster presentations, providing an overview of cutting-edge technologies used to address challenging therapeutic and theoretical issues in neuroscience. NDS-2026 stands out for fostering dialogue between basic and clinical scientists, facilitating these exchanges during both scientific sessions and networking events. The summit aims to be particularly educational and inspiring for young scientists, offering them the chance to interact with leading experts. Germany, the host city, is home to top medical research centers and laboratories and boasts many award-winning ethnic and continental food choices. We are proud to welcome you to this exciting summit and hope you will find the academic and social interactions in Germany rewarding.

## HERE'S WHAT YOU CAN EXPECT IN NDS-2026



Panel discussions



Interactive poster session



Collaborations



Emerging Researcher Forum



Raise an Agenda



Networking during  
customized social hours

# OVERVIEW OF THE NDS-2026 SCHEDULE

July 06, 2026	Day-1
08:00-08:20	<b>Registration Desk Open</b> (Proceed to collect your badge and the conference materials)
08:20-08:30	<b>Opening Note</b>
08:30 Onwords	<b>Plenary Talks</b>
	<b>PS-01: Kenneth Blum</b> Western University College of Medicine, USA
	<b>PS-02: Giulio Maria Pasinetti</b> Icahn School of Medicine at Mount Sinai, USA
	<b>PS-03: Howard Federoff</b> Kenai Therapeutics, USA
25:00 Minutes	<b>Coffee Break</b>
	<b>PS-04: Jeffrey H. Kordower</b> Arizona State University, USA
05:00 Minutes	<b>Session Break</b> <b>Keynote Talks</b>
	<b>KT-01: Sabrina Paganoni</b> Harvard Medical School, USA
	<b>KT-02: Shinichiro Miyazaki</b> Kamiyacho Neurosurgical Clinic, Japan
	<b>KT-03: Niketa A. Patel</b> University of South Florida, USA
50:00 Minutes	<b>Lunch</b>
	<b>Session: Alzheimer's Disease, Dementia and Mild Cognitive Impairment</b>
25:00 Minutes	<b>Coffee Break</b>
	<b>Session: Alzheimer's Disease, Dementia and Mild Cognitive Impairment (AD)</b>
05:00 Minutes	<b>Session Break</b> <b>Poster Presentations Followed by Drinks</b>
19:30-21:30	<b>Social &amp; Networking Dinner (Ticket Required)*</b>

July 07, 2026	Day-2
08:00 Onwords	<b>Keynote Talks</b>
	<b>KT-04: Rajendra D. Badgaiyan</b> Texas Tech University Health Sciences Center, USA
	<b>KT-05: Genichiro Ohashi</b> Ohashi Neurosurgical Clinic, Japan
25:00 Minutes	<b>Coffee Break</b>
	<b>Session: Parkinson's Disease and Other Movement Disorders</b>
	<b>Keynote Talk</b>
	<b>KT-06: Kedar N. Prasad</b> Engage Global Inc., USA
50:00 Minutes	<b>Lunch</b>
	<b>Session: Neurological Disorders: Symptomatology, Pathophysiology and Etiology</b>
	<b>Keynote Talk</b>
	<b>KT-07: Dennis Steindle</b> University of North Carolina, USA
	<b>Session: Neurological Disorders: Symptomatology, Pathophysiology and Etiology</b>
25:00 Minutes	<b>Coffee Break</b>
	<b>Session: Diagnostics of Neurological Disorders: Neuroimaging, Biomarkers and Laboratory Studies</b>
	<b>Keynote Talk</b>
	<b>KT-08: Jin Jun Luo</b> Temple University, USA
	<b>Session: Neurological Disorders: Prevention, Treatment and Therapeutic Options</b>
05:00 Minutes	<b>Session Break</b>
	<b>Session: Neurological Disorders: Prevention, Treatment and Therapeutic Options</b>
	<b>Exhibitor and Sponsor: Product &amp; Research Highlights*</b>

July 08, 2026	Day-3
08:00 Onwords	<b>Session: Autism and Neurodevelopmental Disorders</b> <b>Keynote Talk</b>
	<b>KT-09: Sam Goldstein</b> University of Utah School of Medicine, USA
	<b>Session: Autism and Neurodevelopmental Disorders</b>
25:00 Minutes	<b>Coffee Break</b>
	<b>Session: Autism and Neurodevelopmental Disorders</b>
05:00 Minutes	<b>Session Break</b>
	<b>Session: Epilepsy and Seizure</b>
50:00 Minutes	<b>Lunch</b>
	<b>Session: Multiple Sclerosis, Migraine and Headaches</b>
25:00 Minutes	<b>Coffee Break</b>
	<b>Session: Stroke: Prevention, Treatment and Recovery</b>
	<b>Closing Remark and Departure</b>

**\*Social & Networking Dinner (Ticket Required)**

An interactive networking dinner featuring round-table discussions with committee members, plenary and keynote speakers, and fellow presenters, designed to foster meaningful connections and in-depth discussions on current topics and advances in neuroscience.

**\*Exhibitor and Sponsor: Product & Research Highlights**

This section showcases the latest products, technologies, and research innovations presented by conference exhibitors and sponsors, highlighting their contributions and advancements relevant to the field.

Join the meeting  
To be updated

Meeting ID: To be updated  
Passcode: To be updated

Registrations & Conference Materials Collections

Introduction

## PLENARY TALKS

**Chair:** **Kenneth Blum**, *Western University College of Medicine, USA*



**Kenneth Blum**, *Western University College of Medicine, USA*

**Dr. Kenneth Blum** is an American scientist known for major contributions to psychopharmacology and psychiatric genetics. He holds degrees from Columbia University, Rutgers/NJ Medical School, and a PhD in Neuropharmacology from New York Medical College. With 730+ publications, 17 books, and over 17,000 citations, he is credited with the first genetic link between the dopamine D2 receptor and severe alcoholism (JAMA, 1990) and is often regarded as a founder of psychiatric genetics. He coined “Reward Deficiency Syndrome (RDS)”, developed the patented Genetic Addiction Risk Severity (GARS) test, and holds over 100 global patents including pro-dopamine regulators. Dr. Blum serves as Editor-in-Chief or associate editor for multiple journals and sits on 23 editorial boards. His work has received extensive media recognition and numerous honors, including NIH grants, lifetime achievement awards, and honorary professorships. He is Executive Chairman and CEO of TranspliceGen Therapeutics and was ranked in the top 2% of scientists worldwide by Stanford University (2023).



**Giulio Maria Pasinetti**, *Icahn School of Medicine at , Mount Sinai USA*

**Dr. Giulio Maria Pasinetti**, the Saunders Family Chair and Professor of Neurology at Mount Sinai, holds an MD and PhD from the University of Milan. He directs the NIH-funded Center for Molecular Integrative Neuroresilience and leads the Brain Institute’s Center of Excellence for Novel Neurodiagnostics and Neurotherapeutics. He also serves as Professor of Psychiatry, Neuroscience, and Geriatrics. A globally recognized leader in neurodegeneration research, Dr. Pasinetti has received major honors, including the Alzheimer’s Association Zenith and Temple Awards, Mount Sinai’s Faculty Council Award, and the Charles Dana Alliance Award.



**Howard Federoff**, *Kenai Therapeutics, USA*

**Dr. Howard Federoff** is Chief Medical Officer and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics. He previously served as CEO of Aspen Neuroscience, leading a \$70M Series A for an autologous iPSC Parkinson’s program, and as CEO of Brooklyn ImmunoTherapeutics, where he redirected the company toward iPSC immuno-oncology. He also co-founded Brain Neurotherapy Bio, advancing AAV gene therapies for movement disorders. A leading clinician-scientist and entrepreneur in gene and cell therapies for neurological disease, Dr. Federoff has held senior academic and leadership roles, including Dean, Vice Chancellor for Health Affairs, and EVP for Health Sciences.



**Coffee Break**



**Jeffrey H. Kordower**, *Arizona State University, USA*

**Jeffrey Kordower** is the founding director of the ASU-Banner Neurodegenerative Disease Research Center and the Charlene and J. Orin Edson Distinguished Director at ASU's Biodesign Institute. A leader in neurodegenerative disease research, he has pioneered neural transplantation techniques and advanced understanding of disease mechanisms, gene and stem cell therapies, aging, and learning and memory. He joined ASU after more than 30 years on the faculty at Rush University Medical Center in Chicago.

 **Session Break**

## KEYNOTE TALKS

**Chair:** **Yuko Harada**, *Kawasaki Municipal Ida Hospital, Japan*



**Sabrina Paganoni**, *Harvard Medical School, USA*

### **A New Era for ALS Trials: Innovation, Collaboration, and the Path Forward**

**Dr. Paganoni** is an Associate Professor at Harvard Medical School and a physician-scientist at the Healey Center for ALS, Massachusetts General Hospital, and Spaulding Rehabilitation Hospital. Her research focuses on ALS clinical trials and therapy development, with leadership roles as PI and co-PI of multiple trials, including the world's first ALS platform trial, the HEALEY ALS Platform Trial. She has reported positive results from the CENTAUR trial and co-chairs the global PHOENIX trial. She also leads research in Primary Lateral Sclerosis (PLS) and Hereditary Spastic Paraplegia (HSP), co-chairing the PLS Task Force and PLS Registry of NEALS. Dr. Paganoni has published over 100 peer-reviewed papers, serves on editorial boards of leading journals, and has received multiple national awards for clinical research excellence. She holds board certifications in PM&R, Neuromuscular Medicine, and Electrodiagnostic Medicine.



**Shinichiro Miyazaki**, *Kamiyacho Neurosurgical Clinic, Japan*

### **TBA**

**Dr. Shinichiro Miyazaki** graduated from Juntendo University School of Medicine and trained under renowned neurosurgeon Dr. Takanori Fukushima, becoming certified in Fukushima's keyhole microsurgery in 1989. He has treated countless cases of trigeminal neuralgia and brain tumors. Inspired by Professor John Adler's work, he shifted to stereotactic radiosurgery in 2004 and has since treated over 15,000 patients using the CyberKnife system. Recently invited by Professor Adler to specialize in the next-generation ZAP-X radiosurgery platform, he now serves as Director of Neurosurgery at Kamiyacho Neurosurgical Clinic, providing advanced ZAP-X treatment. He is widely recognized as Japan's leading CyberKnife surgeon and has authored numerous papers and books.



**Niketa A. Patel**, *University of South Florida, USA*

TBA

**Dr. Patel** is a Professor at Morsani College of Medicine, USF and a Research Career Scientist at JAH VA Hospital. Dr. Patel's research interests are in the field of neurodegenerative diseases and metabolic diseases with emphasis on RNA therapeutics. Her research in regenerative medicine with focus on adult human adipose stem cells and its exosomes is amongst the leaders in the field. Her cutting-edge research supports the mission to boost healthcare of individuals worldwide evidenced by continuous federal funding, high impact publications, clinical collaborations. She currently holds 11 patents and over 100 manuscripts, book chapters and abstract publications.



**Lunch**

## Session: Alzheimer's disease, dementia and mild cognitive impairment

**Chair:** **Jin Jun Luo**, *Temple University, PA*

### Rapamycin Treatment for Alzheimer's Disease and Related Dementias: A Pilot Phase 1 Clinical Trial

**Mitzi M. Gonzales**, *Cedars-Sinai Medical Center, USA*

### The Gain-of-function Mutation, T96K, in the TREM2 Gene Increases Risk for Alzheimer's Disease by Leading to Dysfunctional Microglia

**Ana Griuciu**, *Massachusetts General Hospital, USA*

TBA

**Samira Jamalian**, *Genentech Inc., USA*

### From Bedside to Bench: Using Natural Language Processing and Dimensional Psychiatry to Advance Post-mortem Brain Research

**Jonathan Vogelgsang**, *McLean Hospital of Harvard Medical School, USA*

### Developing a Quantitative, High-throughput Platform Using Virus-infected Cerebral Organoids for Neuroinflammation in Alzheimer's Disease

**Elaine T. Lim**, *University of Massachusetts Chan Medical School, USA*

### Inherent Dysfunctional Cellular Energy Metabolism is a Risk Factor for Late-onset Alzheimer's Disease

**Kai-Christian Sonntag**, *McLean Hospital, USA*

### BIN1-RIN3 Interaction Regulates Endosomal Pathology in Human iPSC-derived Neurons

**Raja Bhattacharyya**, *Massachusetts General Hospital, USA*



**Coffee Break**

### Resilience to Alzheimer's Disease by Targeting Adult Hippocampal Neurogenesis

**Se Hoon Choi**, *Harvard Medical School, USA*

### Implementation of Virtual Reality (VR) to Enhance Psychological Well-being in Home Based-primary Care (HBPC) Veterans with Dementia

**Alison G. Kaneshiro**, *VA Pacific Islands Health Care System, USA*

TBA

**Ron Eppes**, *International Association for Indigenous Aging, USA*

### Beyond Traditional Screening: AI-Driven Early Detection of Cognitive Disorders and Dementia

**Laszlo Varga**, *ALSAD Medical, Hungary*

### Association of Spirituality, Quality of Life and Depression in Family Members of Older Adults with Dementia

**Luana Vitro**, *Universidade Federal de São Paulo, Brazil*

## Role of Testosterone Signaling in Microglia: A Potential Role for Sex-related Differences in Alzheimer's Disease

Takashi Kanematsu, *Kyushu University, Japan*

## Iron Stimulation Linked to Pathological Protein Aggregates in the Alzheimer's Brain Offers a Unique Intervention for Multiple Pathologies

Jong-Ki Kim, *Daegu Catholic University, Republic of Korea*

## Eigenvector Centrality Connectivity Patterns indicate Age and APOE4 Carrier Status.

Aida Fall, *University of Geneva, Switzerland*

### **Session Break**



### Poster Presentations Followed by Drinks



#### **NDSP2601** Advancing Dementia Screening for Adults with Down Syndrome

Alexa Gozdoff Spognardi, *Mass General Hospital, USA*

#### **NDSP2602** The Convergence of Autism Spectrum Disorder and Intimate Partner Violence: Neurobiological Implications for Biobehavioral Intervention Development

Hannah Steinke, *The Ohio State University, USA*

#### **NDSP2603** From Digital Dissociative Symptoms to Resilience: A Neuroscience-informed Case Study of Prefrontal Attunement and Recalibration Through Connectedness

Kristina Ray-Bennett, *Indiana University, USA*

#### **NDSP2604** A Student-led Model for Neurological Ultrasound Education

Rachel Pomeranets, *Ohio State University College of Medicine, USA*

#### **NDSP2605** Early and Late Mortality Prognostication in Acute Ischemic Stroke

Bianca Savant, *UND School of Medicine and Health Sciences, USA*

#### **NDSP2606** Multiple Intracranial Hemorrhages with Venous Stagnation on Cerebral Angiogram in Neurosarcoidosis

Haque Shakil, *Northwell Health Staten Island University Hospital, USA*

#### **NDSP2607** A Case of Acute Onset Sensory Loss in a Patient with Positive G1QB Antibodies

Aleksandra Donohue, *MercyOne Des Moines Medical Center, USA*

#### **NDSP2608** Neurologic Implications of GLP-1 Receptor Agonists

Lindsay Guevara, *Mayo Clinic, USA*

#### **NDSP2609** Utilizing Fuzzy C-Means Clustering to Identify Emotional Subtypes of Psychosis

Kelsey Valentine, *Boston University, USA*

#### **NDSP2610** SMART Syndrome and A Unique Presentation: A Case Report and Literature Review

Anneliese Troidle, *University of Connecticut, USA*

#### **NDSP2611** Childhood Trauma, Emotion Dysregulation, and Cannabis Use in Psychosis Risk: A Review and Integrative Model

Peter Levin, *Harvard Medical School/Beth Israel Deaconess Medical Center, USA*

#### **NDSP2612** Oligodendrocyte Maturation Factor Drives Myelination in Mouse Anterior Commissure

Khanh Phan, *The University of Oklahoma Health Sciences Center, USA*

#### **NDSP2613** Speech as a Biomarker - A Logistic Regression Analysis of Potential Linguistic Markers of Dementia

Vikesh K. Patel, *Woodbridge Academy Magnet School, USA*

**NDSP2614** Mood-motor Interactions in Parkinson's Disease: A Scoping Review of Clinical Correlates and Neurobiological Mechanisms

Taylor Rogan, *Yale University, USA*

**NDSP2615** In Silico Identification of Alpha-synuclein Fibril Inhibitors through Large-scale Virtual Screening and Molecular Dynamics Simulations

Ridhaan Palkar, *Sammamish High School, USA*

**NDSP2616** A Viral Wake-up Call in a Patient with Myasthenia Gravis

Neha Gregory, *Medical College of Georgia, USA*

**NDSP2617** Ethnoracial Variation in the Clinical Presentation of Lewy Body Dementia: Findings from a Diverse Cohort in Hawai'i

Elysia Teruya, *Hawai'i Pacific Neuroscience, USA*

**NDSP2618** The Eye as a Window to Brain Health: Can Retinal Imaging and AI Modeling Predict Alzheimer's Disease?

Eniola Awodiya, *University of Oxford, UK*

**NDSP2619** Understanding the Role of Assistive Technologies in Alleviating Caregiver Burden Across Neurodegenerative Diseases

Michael Chan, *University of Waterloo, Canada*

**NDSP2620** UInhibition Effect and Molecular Mechanisms of Imatinib on the A $\beta$ 42

Weiyi Wang, *Peking University, China*

**NDSP2621** Transcranial Magnetic Stimulation as a Potential Strategy to Modulate Development of Alzheimer's Like Pathology Following Spinal Cord Injury

Bhavyasri Varadarajula, *All India Institute of Medical Sciences, India*

**NDSP2622** A Rare Case of Glycogen Storage Disease Type IV

Naila Rahimova, *Scientific Research Institute of Pediatrics, Azerbaijan*

**NDSP2623** Early Diagnosis of Alzheimer's: Machine Learning Analysis Leveraging Structural MRI

Suhail Ahmad Dar, *KREA University, India*

**NDSP2624** Detection of Major Depressive Disorder Using EEG and Machine Learning-based Feature Fusion

Kasturi Barik, *JIS University, India*

**NDSP2625** DMitochondrial Abnormalities in Charcot-Marie-Tooth Disease: Insights from a Family Harboring a Novel GDAP1 Variant

Shivani Sharma, *National Institute of Mental Health and Neurosciences, India*

Join the meeting  
To be updated

Meeting ID: To be updated  
Passcode: To be updated

**KEYNOTE TALKS**

**Chair:** Jin Jun Luo, Temple University, USA



**Rajendra D. Badgaiyan**, Texas Tech University Health Sciences Center, USA

TBA

**Dr. Rajendra D. Badgaiyan** is a psychiatrist and cognitive neuroscientist at Texas Tech University Health Sciences Center, where he serves as Professor and Chair of Psychiatry. He is known for developing a novel brain imaging technique to measure neurotransmitter changes in the living human brain and for his research on dopamine's role in cognition, behavior, and addiction. His expertise spans psychiatry, neuroimaging, addiction, and cognitive neuroscience. A recipient of the Harvard Solomon Prize and India's B.K. Anand Research Prize, he has published over 200 papers and book chapters and authored Neuroscience of the Nonconscious Mind.



**Genichiro Ohashi**, Ohashi Neurosurgical Clinic, Japan

**Surgery and Radiation Therapy for Craniopharyngioma**

**Dr. Genichiro Ohashi** is the director of the Ohashi Neurosurgery Clinic and co-director of the Skull Base Surgery and CyberKnife Radiosurgery programs. He graduated from Hirosaki University School of Medicine and completed his residency in the Department of Neurosurgery at Jikei University School of Medicine. He served as a skull base surgery fellow at the Brain Tumor Research Center for 20 years with the late Professor Takanori Fukushima. Since 1991, he has focused his clinical interests on skull base and pituitary surgery, as well as radiosurgery. Dr. Ohashi treats patients with a wide range of conditions, including cerebrovascular disease, brain tumors, and neurovascular compression syndromes. He has published over 50 papers in the peer-reviewed medical journals.



**Coffee Break**

**Session: Parkinson's Disease and Other Movement Disorders**

**Chair:** Jin Jun Luo, Temple University, PA

**KEYNOTE TALK**



**Kedar N. Prasad**, Engage Global Inc., USA

**Role of a Micronutrient Mixture, Probiotics, Collagen Peptides, Omega3, and CBD in Prevention and Improved Treatment of Parkinson's Disease**

**Dr. Kedar N. Prasad** completed his PhD at the University of Iowa, followed by postdoctoral training at Brookhaven National Laboratory, and later joined the University of Colorado Medical School for teaching and research. His key scientific contributions include showing that elevated cyclic AMP induces terminal differentiation in neuroblastoma cells, and identifying butyric acid and vitamin E succinate as potent anticancer agents. He also demonstrated that high-dose antioxidants can kill cancer cells without harming normal cells. He was invited by the Nobel Prize Committee to submit a nomination in 1982 and became a member of the Royal Society of Medicine in 2017.

**Intrapataminal CaV1.3 RNAi Therapy in Aged Parkinsonism Male and Female Non-human Primates Reverses Parkinsonian Behavioral Deficits and Reveals Evidence of Nigrostriatal Dopamine-phenotype Restoration**

**Kathy Steece-Collier**, *Michigan State University, USA*

**Clinical Considerations in Parkinson's Disease Cell Therapy**

**Jeffrey Schweitzer**, *Massachusetts General Hospital, USA*

**The Genetic Dystonias: Overlapping Phenotypes, Divergent Intracellular Pathologies, and The Effect on Treatment Choice**

**Nutan Sharma**, *Mass General Brigham, USA*

**Can Money Kill Cells?**

**Kristy Martin**, *University of California, USA*

**Development of Clinical-grade Autologous hiPSC-derived Dopaminergic Progenitors for Personalized Cell Therapy in Parkinson's Disease**

**Young Cha**, *Harvard Medical School, USA*

**Aperiodic Activity and High-frequency Oscillations in Basal Ganglia-cortical Circuits in Parkinson's Disease**

**Alan Bush**, *Mass General Brigham, USA*

**Sex and Menopause as Cross-cutting Modifiers of Motor and Non-motor Circuits in Parkinson's Disease: A Multi-Model  $\alpha$ -Synuclein Strategy**

**Roberta Marongiu**, *Weill Cornell Medicine, USA*

**A Common miRNA-mediated Inflammatory Signature Links Gut Dysfunction, Depression, and Parkinson's Disease**

**Analia Bortolozzi**, *Institute of Biomedical Research of Barcelona - CSIC, Spain*

**Incidence, Prevalence and Mortality of Parkinson's Disease in Greece**

**George Makris**, *University of Crete, Greece*

**Prevalence, Demographic Characteristics of Parkinson's disease and Associated Comorbidities. An Analysis of the Colombian Ministry of Health Official Record**

**Angela Rincon**, *Fundación Santa Fe De Bogotá, Colombia*

**The Gut-Brain Axis: New Frontiers in Parkinson's Disease Modulation**

**Sandra Morais Cardoso**, *University of Coimbra, Portugal*

**Health Qigong Exercise on Dual-task Function in Parkinson's Patients**

**Junfan Zhang**, *Beijing Sport University, China*

**Intervention Study of Health Qigong Exercise on Autonomic Dysfunction in Patients with Mild to Moderate Parkinson's Disease**

**Xiaolei Liu**, *Beijing Sport University, China*

**Clinical Analysis of Tear Film Stability and Corneal Nerve Changes in Patients with Parkinson's disease**

**He Wang**, *Affiliated Hospital of Xuzhou Medical University, China*



Chair: TBA

## KEYNOTE TALK



**Dennis Steindler**, *University of North Carolina, USA*

**Exosomes, Stem Cells, Tertiary Lymphoid and Cranioencephalic Functional Lymphoid Units for Restorative Neurology**

**Dr. Dennis A. Steindler** is a neuroscientist at the Tufts Jean Mayer USDA Human Nutrition Research Center on Aging and holds the Joseph J. Bagnor/Shands Professorship of Medical Research in Neurosurgery at the University of Florida. A former Executive Director of the

McKnight Brain Institute, he earned his PhD in neurobiology from UCSF. His research centers on the growth and transplantation of normal and cancer stem cells, with recent work focused on regenerative therapies for Parkinson's disease and brain cancer. Dr. Steindler has served on editorial boards for major neuroscience journals and advises organizations including Accelerate Brain Cancer Cure and the Michael J. Fox Foundation.

**Anatomical and Electrophysiological Convergence of Parietal and Striatal Circuits Linked to Premotor Cortex During Skilled Behavior in Macaques**

**Rosstin K. Afsahi**, *Georgetown University, USA*

**A Case of Vile Vindictive Primary Central Nervous System Vasculitis**

**George C. Diaz**, *Memorial Neuroscience Institute, USA*

**Perioperative Brain at Risk**

**Amanda Faulkner**, *Medical University of South Carolina, USA*

**Brain-cochlea Axis: The Inner Ear as Window to the Brain**

**Arianna Di Stadio**, *UCL, UK*

**Anesthetic Like Ketamine-induced Neurotoxicity and Their Preventive Strategy**

**Jia-Ren Liu**, *Harbin Medical University, China*

**Efficacy of Bortezomib, Cyclophosphamide, and Dexamethasone for Newly Diagnosed POEMS Syndrome Patients**

**Fang Fang**, *Capital Medical University, China*

**Exploring G9a Towards Epigenetic Therapeutics of Alzheimer's Disease**

**Deb Ranjan Banerjee**, *National Institute of Technology Durgapur, India*



**Coffee Break**

Chair: TBA

## KEYNOTE TALK



**Jin Jun Luo**, *Temple University, USA*

**TBA**

**Dr. Jin Jun Luo**, MD, PhD, FAAN, FAANEM, is an associate professor of Neurology and an adjunct associate professor of Pharmacology, and the Director of EMG and Neuromuscular Medicine at Temple University School of Medicine in Philadelphia. He is board certified in neurology, clinical neurophysiology, neuromuscular medicine, and electrodiagnostic medicine. Dr. Luo is a frequent contributor to neurology literature and serves three Editorial Boards and a reviewer for 12 professional journals. Dr. Luo is a member of the Philadelphia Neurological Society, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Clinical Neurophysiology Society.

**Functional Ultrasound Mapping of Septal Neuromodulation Under Hippocampal NMDAR Blockade in a Schizophrenia Model**

Rosstin K Afsahi, *Keck School of Medicine at USC, USA*

**Age-associated Cortical Thinning in Speech Motor Regions Precedes Hippocampal Decline: Implications for Alzheimer's Disease**

Marziye Eshghi, *Massachusetts General Hospital, USA*

**Aberrant Retrotransposon Activity Links Neurodegeneration to Innate Immunity and Reveals Therapeutic Targets in C9orf72-ALS/FTD**

Chiara Scopa, *Jefferson University, USA*

**Diagnosis of Alzheimer's Disease, Parkinson's Disease, Frontotemporal Dementia, and Paranoid Schizophrenia via Complex Network Analysis of EEG Data**

Miguel Angel Vargas Cruz, *Grupo Alianza Empresarial, Mexico*

**Combining Early Lower Eyelid Surgery with Neuromuscular Retraining for Synkinesis Prevention After Facial Palsy: The Role of the Eye in Aberrant Facial Nerve Regeneration**

Arianna Di Stadio, *UCL, UK*

**Brain Computer Interface and Progress in Vietnam**

Hoang-Anh The Nguyen, *Ministry of Science and Technology, Vietnam*

**Phobia, Depression, OCD: Symptoms of One Disorder or Multiple Disorder?**

Neena Shilen, *Sunrise Institute of Medical Sciences, India*

 **Session Break**

**Session: Neurological Disorders: Prevention, Treatment and Therapeutic Options**

**Chair:** TBA

**Flywheel Training: Body Composition and Neuromuscular Performance in Older Women**

Cristian Andres Yanez, *Fitness Academy UDCA, USA*

**Use of CBDA-enriched Cannabinoid Topical Cream for the Treatment of Restless Leg Syndrome**

Debra Kimless, *ChyloCure, USA*

**Total Dietary Food Choice Associations With Grey Matter Volume in UK Biobank**

Auriel A. Willette, *Rutgers University, USA*

**Neurophenomenology in Retraining Musicians with Task-Specific Focal Dystonia: Three Cases**

Sang-Hie Lee, *University of South Florida, USA*

**Evaluation of Non-pharmacological Interventions for Community-dwelling Individuals with Dementia Experiencing Sleep Disturbances: An Updated Systematic Review**

Patton Childers II, *University of Alabama/Piedmont Healthcare, USA*

**Neuropsychological Assessment of Higher Cortical Functions: An Early Interventional Approach To Prevent Mild Cognitive Impairment In The Mexican Population**

Rodolfo Gonzalez Munoz, *University of Valle de Mexico, Mexico*

**Euglycemia as a Prerequisite for Optimal Antioxidant and Anti-neuroinflammatory Treatment with Resveratrol in the Prevention of Neurodegenerative Diseases – Rationale from an In-vitro Study**

Dariusz Szukiewicz, *Medical University of Warsaw, Poland*

**Targeting Macrophage Migration Inhibitory Factor (MIF) as a Novel Therapeutic Target in ALS**

Adrian Israelson, *Ben-Gurion University of the Negev, Israel*

**Mechanism-Driven Nanoformulations for Cognitive Impairment Induced by Intermittent Hypoxia and Periodontitis**

Jun Gao, *Fudan University, China*

**Role of Electrodiagnostic Modalities in the Detection of Nasal Obstruction**

Hadi Ghanbari, *Iran University of Medical Sciences, Iran*

Join the meeting  
To be updated

Meeting ID: To be updated  
Passcode: To be updated

**Session: Autism and Neurodevelopmental Disorders**

**Chair:** TBA

**KEYNOTE TALK**



**Sam Goldstein**, *University of Utah School of Medicine, USA*

**Neurobiology Meets the Clinic: Making Informed Exam Room Decisions in Autism Spectrum Disorder**

**Dr. Sam Goldstein, PhD**, earned his doctorate in School Psychology from the University of Utah and is a licensed and board-certified pediatric neuropsychologist. He is a Fellow of the American Psychological Association and the National Academy of Neuropsychology, and serves as an Adjunct Assistant Professor of Psychiatry at the University of Utah School of Medicine. Dr. Goldstein has authored over 50 publications, numerous textbook chapters, peer-reviewed articles, and psychological assessment tools. He is the former Editor-in-Chief of the *Journal of Attention Disorders* and has served since 1980 as Clinical Director of the Neurology, Learning and Behavior Center in Salt Lake City, conducting over 700 neuropsychological evaluations annually.

**Neurobiological Basis of Bioelectronic Medicine in Treating Pediatric ADHD and Autism**

**Alli San Roman**, *University of Notre Dame, USA*

**Development of a Novel Self-report Tool to Aid in the Assessment of Autism in Adulthood: The Autism Spectrum Trait Scale**

**Salayna Abdallah**, *Kent State University and University Hospitals, USA*

**Investigating the Effects of Two Computerized Interventions on Cognitive and Emotional Measures in Children with Autism**

**Lilach Shalev**, *Tel Aviv University, Israel*

**Autism Spectrum Disorder Detection Using Connectivity Features Maps from EEG Signals**

**Nazmul Siddique**, *Ulster University, United Kingdom*

**The Intestinal Microbiota and Gut-brain Axis in Autism Spectrum Disorder (ASD): An Integrative Review**

**Luis Otavio Santos Camargo**, *PUCRS, Brazil*

**Effects of Autism on the Psychological Health and Family Structure of Caregivers**

**Maira Alejandra Lopez Castellar**, *Fundacion Universitaria del Area Andina, Colombia*

**Loneliness from the Perspective of Young People with Autism and/or ADHD**

**Suzanne Stewart**, *Edith Cowan University, Australia*

**An Analysis of Newspaper Reports on the Success of Individuals with Autism Spectrum Disorder**

**Gulsen Sencan**, *Istanbul 29 Mayis University, Turkey*



**Coffee Break**

**Autism in Urban Planning: In Search of a Theoretical Framework**

**Mohammad Sarraf**, *RISE Research Institutes of Sweden, Sweden*

**Association of Deep Phenotypical Features with Severity of Autism in Children**

**Najwa Anwaar**, *Wexford General Hospital, Ireland*

**Maintenance Electroconvulsive Therapy for Treatment-resistant Irritability in Autism Due to Depression in an Adolescent: A Case Study**

**Ipek Ege Gurel Ficicioglu**, *Istanbul Bakirkoy Prof. Dr. Mazhar Osman Research and Teaching Hospital for Psychiatry, Neurology and Neurosurgery, Turkiye*

**Cross-cohort Machine Learning Discovery of Gut Microbiome Biomarkers for Autism Spectrum Disorder Diagnosis**

**Pengcheng Fu**, *Hainan University, China*



---

**Session: Epilepsy and Seizure**

**Chair: TBA**

**The Brain-heart Connection: Value of Concurrent ECG and EEG Monitoring in Epilepsy Management**

**Trudy D. Pang**, *Beth Israel Deaconess Medical Center, USA*

**Simultaneous Craniotomy for Resection and Placement of Responsive Neurostimulation for Treatment of Medically Refractory Epilepsy: Illustrative Cases**

**Catherine Gwinn**, *University of Washington, USA*

**Late-Onset Myoclonic Epilepsy with Ragged Red Fiber-Spectrum Mitochondrial Disease: A Case Report**

**Raymond Yuh-Shyan Chiang**, *California Northstate University College of Medicine, USA*

**Epilepsy Before Neurology Diagnosing And Treating The 'Sacred Disease' In Antiquity**

**Fabio Spadini**, *University of Fribourg, Switzerland*

**Mechanism-based Therapy for Oligogenic Refractory Epilepsy**

**Jing-Da Qiao**, *Guangzhou Medical University, China*

**A Randomized Controlled Trial of Loading Dose Alone Versus Pritchard Regimen of Magnesium Sulphate, for Seizure Prophylaxis in Severe Preeclampsia**

**Habiba Ibrahim Abdullahi**, *University Of Abuja Teaching Hospital, Nigeria*

**Scalp High-frequency Oscillations as Predictors of Seizure-free Duration in Pediatric Epilepsy**

**Keisuke Maeda**, *Fujita Health University, Japan*

**TBA**

**Lei Chen**, *Sichuan University, China*



---

**Session: Multiple Sclerosis, Migraine and Headaches**

**Chair: TBA**

**Forty Years of Real-world Experience with 70,000 Therapeutic Plasma Exchange Procedures in Autoimmune Neurological Disorders**

**Bhupendra Khatri**, *Center for Neurological Disorders, USA*

**Measuring Health-related Quality of Life in Multiple Sclerosis Over Time: How Do You Know If There Has Been A Clinically Relevant Change?**

**Carolyn Young**, *University of Liverpool, UK*

**Efficacy of Galcanezumab in Proline-rich Transmembrane Protein 2 (PRRT2)-associated Familial Hemiplegic Migraine: A Case Series**

*Costanza Sottani, Agostino Gemelli University Hospital, Italy*

**Exploring the Neuroprotective Role of Heat-killed Lactobacilli in Multiple Sclerosis**

*Zahra Fegghi, University of Isfahan, Iran*



**Coffee Break**

## **Session: Stroke: Prevention, Treatment and Recovery**

**Chair: TBA**

**Long-term Outcomes of Paired Vagus Nerve Stimulation for Motor Rehabilitation After Stroke**

*Matthew Picard-Fraser, MGH Institute of Health Professions, USA*

**A Novel Approach to Gait Rehabilitation: Cortical Priming for Better Step Initiation in Chronic Stroke**

*Shih-Chiao Tseng, University of Texas Medical Branch, USA*

**TBA**

*Mellanie Springer, University of Michigan, USA*

**Thromboembolic Events and Vascular Dementia in Patients with Atrial Fibrillation and Low Apparent Stroke Risk**

*Alastair R. Mobley, University of Birmingham, UK*

**Enriched Environment Improves Cognitive Impairment After Stroke in Mice by Modulating the Ventral Hippocampal-medial Prefrontal Cortex Glutamatergic Pathway**

*Xin Wang, Taizhou Fourth People's Hospital, China*

**Efficacy and Safety of Intermittent Hypoxic Exposures in Comprehensive Rehabilitation of Patients in the Long Term Following a Stroke**

*Malachi Nyamukondiwa, Sechenov University, Russian Federation*

**Risk Factors and Management of Stroke in Young Adults**

*Anusha Thomas, Christian Medical College, India*

## **Closing Remark and Departure**

**Disclaimer: Please note that this is a preliminary schedule and subject to change. Final adjustments may be made at the last minute without prior notification.**

Organized by



**UNITED**

A non-profit organization

Scientific  
Group

**USG United Scientific Group**

(A non-profit organization)

#8105 Rasor Blvd, Suite 112, PLANO, TX 75024, USA

Tel: +1-469-854-2280/81; Fax: +1-469-854-2278;

Email: [nds@uniscigroup.net](mailto:nds@uniscigroup.net); Web: <https://nds.unitedscientificgroup.org/>